Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 56 | ECE2018 | Next issue

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

Card image cap
ECE 2018, 19 - 22 May 2018; Barcelona, Spain

Oral Communications

Cardiovascular aspects of endocrine diseases

ea0056oc10.1 | Cardiovascular aspects of endocrine diseases | ECE2018

Glucocorticoid replacement-doses and cardiovascular events in autoimmune Addison’s disease – a population based retrospective cohort study

Skov Jakob , Sundstrom Anders , Ludvigsson Jonas , Kampe Olle , Bensing Sophie

Objective: Mortality in autoimmune Addison’s disease (AAD) is increased twofold compared to matched populations. Cardiovascular disease (CVD) is the most common cause of death, but little is known of cardiovascular morbidity. Inadequate glucocorticoid replacement has been implicated in the increased risk of CVD, but evidence is lacking. The objective of this study was to examine cardiovascular morbidity and mortality in AAD, and to investigate the effects of glucocorticoi...

ea0056oc10.2 | Cardiovascular aspects of endocrine diseases | ECE2018

Canagliflozin attenuates the progression of atherosclerosis via reducing hyperlipidaemia and inflammation process in ApoE KO Mice

Nasiri-Ansari Narjes , Dimitriadis Georgios K. , Agorogiannis George , Perrea Despina , Daikos George , Papavassiliou Athanasios G. , Kaltsas Gregory , Randeva Harpal S. , Kassi Eva

Introduction: Treatment with sodium glucose co-transporter2(SGLT2) inhibitors was found to reduce the incidence of cardiovascular events in diabetic patients.Herein, we investigated the effects of long-term treatment with canagliflozin on atherosclerosis development in the aorta of Apolipoprotein E knockout (Apo-E(−/−)) mice as well as on biochemical and immunohistochemical markers related to atherosclerosis.Methods: At 4 weeks of ...

ea0056oc10.3 | Cardiovascular aspects of endocrine diseases | ECE2018

ARMC5 variants and risk of hypertension in African Americans: Minority Health-GRID study

Zilbermint Mihail , Gaye Amadou , Berthon Annabel , Hannah-Shmouni Fady , Faucz Fabio , Minority Health-GRID Network Fabio , Davis Adam , Gibbons Gary , Lodish Maya , Stratakis Constantine

Context: Hypertension is one of the most preventable risk factors for cardiovascular disease and death. Up to 42.1% of non-Hispanic African-American subjects have hypertension. We recently found that germline ARMC5 variants may play a role in primary aldosteronism, particularly in African-Americans.Objective: We investigated a cohort of participants in the Minority Health Genomics and Translational Research Bio-Repository Database (MH-GRID) stud...

ea0056oc10.4 | Cardiovascular aspects of endocrine diseases | ECE2018

Improvement in the control of hypertension in diabetic patients screened for hyperaldosteronism

Jimenez Ines , Crespo Irene , Cuesta Martin , Elvira Carlos , de Miguel Paz , Santiago Alejandro , Fernandez Luzdivina , de Parayuelo Maria Victoria Saez , Calle Alfonso , Runkle Isabelle

Introduction: Control of hypertension (HT) is essential to reduce cardiovascular events in diabetic patients (DPts). However, studies indicate that only 50% of DPts with treated hypertension present adequate blood pressure (BP) control. Yet Endocrine-Society-Guideline (ESG) screening for primary hyperaldosteronism (PHA) is rarely applied. Furthermore, in patients with essential hypertension (EH), longer-acting hypertension medication (HM) improves 24-hour BP when compared to r...

ea0056oc10.5 | Cardiovascular aspects of endocrine diseases | ECE2018

Increased risk of antithyroid drug-induced agranulocytosis with amiodarone

Gershinsky Michal , Lavi Idit , Shapira Chen , Gronich Naomi

Aim: Antithyroid drugs (ATD) methimazole and propylthiouracil (PTU) are the drugs of choice for treatment of hyperthyroidism. Agranulocytosisis, the most severe side effect of these medications, occurs in 0.2–0.5% of patients. ATDs are used also in patients with amiodarone-induced thyrotoxicosis (AIT). Our objective was to evaluate the risk for agranulocytosis, associated with ATDs, in patients with AIT, and to compare the risk with the risk of ATD-associated agranulocyto...